glp-1 and ibs-c GLP-1s, Gut Motility & IBS — Noisy Guts Semaglutide, GLP-1 Drugs, and IBS:

Hypermutation in pathogenic bacteria

Scheidweiler, K

Dahlgren M, Khosroshahi A, Nielsen GP, Deshpande V, Stone JH

Why Employers Are Zeroing In On GLP-1s The numbers tell the story: 40% of US adults are living with obesity, with projections closer to 50% by 2030 Employers spend $6,472 more per year on employees with obesity than on healthy-weight employees across medical, productivity, disability, and workers comp Individuals who use GLP-1s can lose between 2.5% and 20% of their initial body weight when taking the medication as instructed Employers want to support prevention, not wait until employees are sicker to qualify for care